Work

Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer

Year: 2010

Type: article

Abstract: Prostate cancer is the second leading cause of cancer death among men in the United States. Standard-of-care chemotherapy for metastatic castration-resistant prostate cancer is associated with significant but modest survival benefit, indicating a need for alternative and/or additional approaches. The use of therapeutic cancer vaccines for the treatment of prostate cancer represents a novel targeted therapeutic approach. Whereas vaccine strategies are being developed for the treatment of various stages of prostate cancer, this article focuses on novel vaccine strategies for castration-resistant prostate cancer that have been translated into late-stage clinical studies.

Source: Clinical and Translational Science

DOI: 10.1111/j.1752-8062.2010.00186.x

Authors: Julia Rotow, Sofia R. Gameiro, Ravi A. Madan, James L. Gulley, Jeffrey Schlom, James W. Hodge

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute